Onconova Therapeutics Inc

NASDAQ:ONTX   4:00:00 PM EDT
0.85
+0.03 (+3.53%)
7:05:45 PM EDT: $0.90 +0.04 (+5.00%)
Earnings Announcements

Onconova Therapeutics Reports Third Quarter 2022 Financial Results

Published: 11/14/2022 21:47 GMT
Onconova Therapeutics Inc (ONTX) - Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined With Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update.
Onconova Therapeutics Inc- Initiation of Phase 1/2a Endometrial Cancer Trial Expected in 1q23; Preliminary Data Expected 4q23.
Revenue is expected to be $0.08 Million
Adjusted EPS is expected to be -$0.28

Next Quarter Revenue Guidance is expected to be $0.1 Million
Next Quarter EPS Guidance is expected to be -$0.30

More details on our Analysts Page.